Learn About MS Treatment Options
Understanding Multiple Sclerosis and Why Treatment Matters Multiple sclerosis (MS) is a disease where the immune system mistakenly attacks the protective cov...
Understanding Multiple Sclerosis and Why Treatment Matters
Multiple sclerosis (MS) is a disease where the immune system mistakenly attacks the protective covering around nerve fibers in the brain and spinal cord. This damage disrupts communication between the brain and the rest of the body. According to the National MS Society, approximately 2.3 million people worldwide have MS, with about 1 million living in the United States. The disease most commonly appears between ages 20 and 50, though it can develop at any age.
MS affects everyone differently. Some people experience mild symptoms and long periods without new symptoms, while others face more serious challenges that change over time. Symptoms can include fatigue, difficulty walking, numbness, vision problems, and cognitive changes. Because MS is unpredictable, many people benefit from treatment as early as possible, even if symptoms seem minor.
Treatment for MS focuses on two main goals: slowing disease progression and managing individual symptoms. Disease-modifying therapies (DMTs) work by reducing the number of relapses and slowing disability progression. Symptom management treatments address specific problems like pain, fatigue, or muscle stiffness. Understanding what different treatments do helps people work with their healthcare providers to make informed decisions about their care.
The type of MS a person has affects which treatments might work best. Relapsing-remitting MS (RRMS) is the most common form, affecting about 85% of people at initial diagnosis. Progressive forms include secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive-relapsing MS (PRMS). Each form has different treatment approaches because the underlying disease activity varies.
Practical Takeaway: Learning about MS types and how treatments work provides important background for understanding your options. Talk with your neurologist about which type of MS you have and what that means for treatment decisions.
Disease-Modifying Therapies: How They Work
Disease-modifying therapies (DMTs) are medications designed to reduce MS disease activity. They work in different ways depending on how they interact with the immune system. Some DMTs reduce the number of immune cells attacking the nervous system. Others change how immune cells function or move through the body. Research shows that starting DMT treatment early—even with mild symptoms—may lead to better long-term outcomes than waiting.
There are several categories of DMTs available. Interferon-based medications like interferon beta-1a and interferon beta-1b have been used to treat MS for over 25 years. These medications stimulate the immune system in ways that reduce inflammation. Glatiramer acetate works by creating a substance similar to myelin, which may redirect immune cells away from attacking the nervous system.
Monoclonal antibodies are laboratory-created proteins that target specific parts of the immune system. Natalizumab prevents certain immune cells from crossing the blood-brain barrier. Alemtuzumab depletes specific immune cells over time. Ocrelizumab targets B cells, a type of immune cell involved in MS. These medications typically require infusions or injections given by healthcare providers in clinical settings.
Oral medications offer another option for DMT treatment. Fingolimod, teriflunomide, and dimethyl fumarate are tablets taken at home. Cladribine is an oral medication given in short courses. These options may appeal to people who prefer not to use injections or infusions, though they may have different side effect profiles than other DMTs.
The choice between different DMTs depends on several factors: the type and severity of MS, previous treatment responses, potential side effects, lifestyle preferences, and other health conditions. Some DMTs work better for certain types of MS. For example, natalizumab may be particularly effective for RRMS but is not used for PPMS. Regular monitoring helps determine whether a chosen DMT is working and whether adjustments might be needed.
Practical Takeaway: DMTs are the foundation of MS treatment for many people. Ask your healthcare team about the different categories of DMTs and which options might match your specific situation.
Symptom Management and Supportive Treatments
While disease-modifying therapies address the underlying disease process, other treatments manage specific MS symptoms that affect quality of life. Fatigue is the most common MS symptom, reported by 75-95% of people with MS according to the Multiple Sclerosis Foundation. This fatigue differs from normal tiredness—it can be overwhelming and unpredictable. Medications like amantadine and modafinil may provide some relief. Energy management techniques, such as pacing activities and prioritizing tasks, also help many people.
Spasticity (muscle stiffness and involuntary muscle contractions) affects many people with MS. Physical therapy and stretching routines form the first line of management. If these approaches aren't sufficient, medications like baclofen, tizanidine, or dantrolene may reduce muscle tension. Some people benefit from botulinum toxin injections for localized spasticity. In severe cases, intrathecal baclofen pumps deliver medication directly to the spinal cord.
Pain occurs in 40-50% of people with MS and can take several forms. Neuropathic pain (nerve pain) may respond to medications like gabapentin or pregabalin. Musculoskeletal pain from muscle tension or altered movement patterns improves with physical therapy, occupational therapy, or massage. Trigeminal neuralgia (facial pain) sometimes responds to carbamazepine or other anti-seizure medications. Pain management often works best when combining medication with non-medication approaches like exercise and relaxation techniques.
Cognitive changes affect thinking, memory, attention, or processing speed in about 40-70% of people with MS. While no medication specifically treats MS-related cognitive issues, speech-language pathologists can teach strategies for memory improvement and organization. Some research suggests cognitive rehabilitation programs may help. Depression and anxiety, which commonly occur with MS, respond well to therapy and medications like antidepressants.
Bladder and bowel problems affect many people with MS. Urinary symptoms range from frequency to urgency to incomplete emptying. Treatment options include timed voiding, fluid management, catheterization, and medications like oxybutynin. Constipation responds to dietary changes, increased water intake, and stool softeners. Working with healthcare providers who understand MS helps develop an effective management plan.
Practical Takeaway: Symptom management is personal—what works for one person may not work for another. Keep track of your symptoms and discuss them with your healthcare team to find the best combination of treatments for your needs.
Treatment by MS Type: Tailoring Approaches
Relapsing-remitting MS (RRMS) is characterized by periods of new or worsening symptoms (relapses) followed by periods of partial or complete recovery (remission). About 85% of people receive an initial RRMS diagnosis. RRMS typically responds well to disease-modifying therapies. Many DMT options are available for RRMS treatment. Studies show that people with RRMS who start DMT treatment early tend to have fewer relapses and slower disability progression than those who delay treatment.
Secondary progressive MS (SPMS) develops when RRMS transitions to a progressive course. In SPMS, disability gradually worsens with or without relapses. Historically, few effective treatments existed for SPMS. However, ocrelizumab has shown benefit in reducing progression in some people with SPMS. Other DMTs used for RRMS may also be continued in SPMS to manage any remaining relapses. Symptom management becomes increasingly important as disability progresses.
Primary progressive MS (PPMS) involves gradual disability worsening from disease onset, without relapses or remissions. PPMS accounts for about 10-15% of MS cases. Treatment options for PPMS are more limited than for RRMS. Ocrelizumab is currently the main DMT approved specifically for PPMS, based on clinical trial evidence showing it slows disability progression. Other DMTs used for RRMS have not shown clear benefit in PPMS. Symptom management and rehabilitation therapies play especially important roles in PPMS care.
Progressive-relapsing MS (PRMS) involves steady disability progression from disease onset with occasional relapses. PRMS is the least common form, occurring in about
Related Guides
More guides on the way
Browse our full collection of free guides on topics that matter.
Browse All Guides →